The recognized global leader in neuromodulation devices to treat blindness, the company leverages its 20 years of technology innovation to develop devices to treat the broadest population of sight-impaired individuals. Inspired by personal connections with a retinitis pigmentosa diagnosis, Second Sight has researched, designed and created the world’s first FDA and CE Mark approved device for providing artificial vision in people with late-stage RP.